Loading...
•
Sep 30, 2023
Ocugen Q3 2023 Earnings Report
Ocugen reported its Q3 2023 financial results, highlighting pipeline progress and advancements in gene and cell therapies.
Key Takeaways
Ocugen reported a net loss of $14.162 million, or $0.06 per share, for the third quarter of 2023. The company's cash, cash equivalents, and investments totaled $53.5 million as of September 30, 2023. Ocugen is advancing its pipeline, with OCU400 showing promising data and OCU500 being selected by NIAID for clinical trials.
OCU400 demonstrated a favorable safety and tolerability profile in RP and LCA subjects.
83% of subjects in the OCU400 Phase 1/2 study showed stabilization or improvement in BCVA, MLMT, or LLVA in treated eyes.
OCU500, Ocugen’s inhaled mucosal vaccine candidate for COVID-19, was selected by NIH/NIAID’s Project NextGen for inclusion in clinical trials.
Ocugen is preparing to start Phase 3 for OCU400, begin dosing patients for OCU410 and OCU410ST, and initiate the Phase 1 trial for OCU500 in collaboration with NIAID.
Forward Guidance
Ocugen is focused on advancing its pipeline of gene and cell therapies, biologics, and vaccines. Key priorities include initiating Phase 3 for OCU400, dosing patients for OCU410 and OCU410ST, and starting the Phase 1 trial for OCU500 in collaboration with NIAID.
Positive Outlook
- Initiating Phase 3 clinical trial for OCU400 in early 2024.
- Expanding OCU400 Phase 3 clinical trial for LCA patients in the second half of 2024.
- Dosing patients in Phase 1/2 trials for both OCU410 and OCU410ST by the end of 2023.
- Initiating Phase 1 clinical trial for OCU200 in the first half of 2024, contingent on the lift of the FDA hold and adequate availability of funding.
- Beginning Phase 3 clinical trial for NeoCart® in the second half of 2024.
Challenges Ahead
- Phase 1 clinical trial for OCU200 is contingent on the lift of the FDA hold and adequate availability of funding.
- Clinical development activities are subject to risks and uncertainties.
- Success and data announcements of current ongoing preclinical and clinical trials are not guaranteed.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...